Semisynthetic sensor proteins enable metabolic assays at the point of care
Monitoring metabolites at the point of care could improve the diagnosis and management of numerous diseases. Yet for most metabolites, such assays are not available. We introduce semisynthetic, light-emitting sensor proteins for use in paper-based metabolic assays. The metabolite is oxidized by nicotinamide adenine dinucleotide phosphate, and the sensor changes color in the presence of the reduced cofactor, enabling metabolite quantification with the use of a digital camera. The approach makes any metabolite that can be oxidized by the cofactor a candidate for quantitative point-of-care assays, as shown for phenylalanine, ...
Source: ScienceNOW - September 13, 2018 Category: Science Authors: Yu, Q., Xue, L., Hiblot, J., Griss, R., Fabritz, S., Roux, C., Binz, P.-A., Haas, D., Okun, J. G., Johnsson, K. Tags: Biochemistry, Medicine, Diseases reports Source Type: news
Matter: Scientists Are Retooling Bacteria to Cure Disease
By manipulating DNA, researchers are trying to create microbes that, once ingested, work to treat a rare genetic condition — a milestone in synthetic biology. (Source: NYT Health)
Source: NYT Health - September 4, 2018 Category: Consumer Health News Authors: CARL ZIMMER Tags: Digestive Tract Microbiology Bacteria Synthetic Biology Genetic Engineering Phenylketonuria (PKU) E Coli (Bacteria) Biotechnology and Bioengineering Massachusetts Institute of Technology Collins, James J Source Type: news
Synthetic Bacteria Help Treat Phenylketonuria in Mice
The genetically engineered probiotic, already in clinical trials, may ease patients' strict dietary regimes. (Source: The Scientist)
Source: The Scientist - August 17, 2018 Category: Science Tags: News & Opinion Source Type: news
Synlogic data shows 40% reduction in disability-causing disease in mice
As Cambridge biotech Synlogic begins human trials, pre-clinical data released this week shows that a probiotic pill containing a beneficial strain of E.Coli could reduce the root problem of a hereditary disease that causes intellectual disabilities by 40 percent.
Synlogic Inc (Nasdaq: SYBX) is developing probiotic medications to treat an array of metabolic disorders, including the hereditary disease phenylketonuria (PKU). The disease causes harmful levels of amino acids to build up, leading to permanent… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 16, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news
What Causes School Failure?
Discussion
“Literacy is traditionally meant as the ability to read and write. The modern term’s meaning has been expanded to include the ability to use language, numbers, images, computers, and other basic means to understand, communicate, gain useful knowledge, solve mathematical problems and use the dominant symbol systems of a culture.”
The earliest written communication was in 3500-3000 BCE, with the earliest alphabet being from 1200-750 BCE. Although the percentage of the world’s adult literacy rate is increasing each decade by ~5%, “…from 55.7 per cent in 1950 to 86.2 per cent in ...
Source: PediatricEducation.org - July 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
New Treatments for Phenylketonuria Aim to Loosen Reins on Strict Diet
Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder. (Source: The Scientist)
Source: The Scientist - May 29, 2018 Category: Science Tags: News Analysis Source Type: news
New Treatments for Phenylketonuria Aim to Loosen Reigns on Strict Diet
Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder. (Source: The Scientist)
Source: The Scientist - May 29, 2018 Category: Science Tags: News Analysis Source Type: news
OHSU to participate in clinical trial for potentially 'life-transforming' drug
Oregon Health& Science University is part of a clinical trial for a drug approved this week for a rare and serious genetic disorder called phenylketonuria, or PKU.
The Food and Drug Administration approved Palynziq, a daily enzyme injection for adults with PKU.
The disease affects about 1 in 10,000 to 15,000 people in the U.S. All newborns are screened for the disease, among others, using a “heel stick” blood draw within 24 to 48 hours after birth.
Pat ients are unable to break down an amino… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 25, 2018 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news
OHSU to participate in clinical trial for potentially 'life-transforming' drug
Oregon Health& Science University is part of a clinical trial for a drug approved this week for a rare and serious genetic disorder called phenylketonuria, or PKU.
The Food and Drug Administration approved Palynziq, a daily enzyme injection for adults with PKU.
The disease affects about 1 in 10,000 to 15,000 people in the U.S. All newborns are screened for the disease, among others, using a “heel stick” blood draw within 24 to 48 hours after birth.
Pat ients are unable to break down an amino… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 25, 2018 Category: American Health Authors: Elizabeth Hayes Source Type: news
FDA Approves Palynziq for Phenylketonuria
FRIDAY, May 25, 2018 -- Palynziq (pegvaliase-pqpz) has been approved by the U.S. Food and Drug Administration to treat phenylketonuria, or PKU.
Palynziq is a novel enzyme therapy for adult patients with PKU with uncontrolled blood phenylalanine... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 25, 2018 Category: Pharmaceuticals Source Type: news
FDA OKs Novel Enzyme Therapy for Rare Disease Phenylketonuria FDA OKs Novel Enzyme Therapy for Rare Disease Phenylketonuria
Pegvaliase-pqpz (Palynziq) helps address a significant, unmet need in phenylketonuria (PKA) patients whose blood levels of PKA cannot be controlled with current treatment options, the FDA says.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
New Treatment, Palynziq (Pegvaliase-pqpz), Approved for Rare Disease PKU
FRIDAY, May 25, 2018 -- Palynziq (pegvaliase-pqpz) has been approved by the U.S. Food and Drug Administration to treat phenylketonuria, commonly called PKU.
People with the rare yet serious inherited disorder can ' t break down an amino acid called... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 25, 2018 Category: General Medicine Source Type: news
FDA approves BioMarin rare metabolic disorder drug, shares rise
(Reuters) - U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours. (Source: Reuters: Health)
Source: Reuters: Health - May 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves a new treatment for PKU, a rare and serious genetic disease
The FDA today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU). (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 24, 2018 Category: American Health Source Type: news
FDA Approves Palynziq (pegvaliase-pqpz) for the Treatment of Adults with Phenylketonuria
May 24, 2018 - The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an inability to break down... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 24, 2018 Category: Drugs & Pharmacology Source Type: news
